Keywords: astrazeneca, intranasal, form, zomig, answers, pressing, need

AstraZeneca's intranasal form of Zomig answers pressing need in migraine

Article | 04 July 2001

Print This

AstraZeneca's new nasal spray formulation of its serotonin 5-HT1B/1Dreceptor agonist Zomig (zolmitriptan) looks set to offer a fast ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in